|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2009-6-11
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The combination of radiotherapy plus long-term medical suppression of androgens (> or = 2 years) improves overall survival in patients with locally advanced prostate cancer. We compared the use of radiotherapy plus short-term androgen suppression with the use of radiotherapy plus long-term androgen suppression in the treatment of locally advanced prostate cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:AkdasAtifA,
pubmed-author:BollaMichelM,
pubmed-author:ColletteLaurenceL,
pubmed-author:EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group,
pubmed-author:GezEliahuE,
pubmed-author:KariakineOlegO,
pubmed-author:MauerMurielle EME,
pubmed-author:MusatElenaE,
pubmed-author:NetoTT,
pubmed-author:OddensJorgJ,
pubmed-author:PiérartMarianneM,
pubmed-author:PoortmansPhilip M PPM,
pubmed-author:SoeteGuyG,
pubmed-author:Van TienhovenGeertjanG,
pubmed-author:Van den BerghAlphonsus C MAC,
pubmed-author:de ReijkeTheodorus MTM,
pubmed-author:van der Steen-BanasikElsbietha MEM
|
|
pubmed:copyrightInfo |
2009 Massachusetts Medical Society
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
11
|
|
pubmed:volume |
360
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2516-27
|
|
pubmed:dateRevised |
2009-9-21
|
|
pubmed:meshHeading |
pubmed-meshheading:19516032-Adult,
pubmed-meshheading:19516032-Aged,
pubmed-meshheading:19516032-Aged, 80 and over,
pubmed-meshheading:19516032-Androgen Antagonists,
pubmed-meshheading:19516032-Anilides,
pubmed-meshheading:19516032-Combined Modality Therapy,
pubmed-meshheading:19516032-Disease-Free Survival,
pubmed-meshheading:19516032-Drug Administration Schedule,
pubmed-meshheading:19516032-Flutamide,
pubmed-meshheading:19516032-Follow-Up Studies,
pubmed-meshheading:19516032-Gonadotropin-Releasing Hormone,
pubmed-meshheading:19516032-Heart Diseases,
pubmed-meshheading:19516032-Humans,
pubmed-meshheading:19516032-Male,
pubmed-meshheading:19516032-Middle Aged,
pubmed-meshheading:19516032-Nitriles,
pubmed-meshheading:19516032-Proportional Hazards Models,
pubmed-meshheading:19516032-Prostatic Neoplasms,
pubmed-meshheading:19516032-Quality of Life,
pubmed-meshheading:19516032-Radiotherapy, Conformal,
pubmed-meshheading:19516032-Tosyl Compounds,
pubmed-meshheading:19516032-Treatment Failure
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Duration of androgen suppression in the treatment of prostate cancer.
|
|
pubmed:affiliation |
Centre Hospitalier Régional Universitaire de Grenoble, Grenoble, France. mbolla@chu-grenoble.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
